Welcome to our dedicated page for 60 Degrees Pharm news (Ticker: SXTPW), a resource for investors and traders seeking the latest updates and insights on 60 Degrees Pharm stock.
News for 60 Degrees Pharmaceuticals, Inc. (warrants: SXTPW) centers on its activities as a pharmaceutical company focused on developing and commercializing medicines for vector-borne diseases. Company announcements repeatedly highlight work in malaria prevention through its FDA-approved product ARAKODA (tafenoquine), as well as clinical research programs in babesiosis, an emerging tick-borne illness for which no FDA-approved treatment currently exists.
Investors and observers following SXTPW-related news will see updates on clinical trial milestones, including the B-FREE Chronic Babesiosis Study (NCT06656351) and other tafenoquine studies in hospitalized and relapsing babesiosis patients. Releases describe study designs, enrollment progress, and early findings such as Babesia detection rates in chronic fatigue cohorts or parasite status in individual patients completing treatment regimens.
Company news also covers commercial and marketing developments for ARAKODA, such as expansion of inside sales teams, partnerships with platforms like GoodRx to broaden offer visibility, and digital marketing campaigns aimed at prescribers. Financial updates, including quarterly results and commentary on product demand trends, appear alongside these operational highlights.
Regulatory and capital markets items form another important news category. Examples include announcements of reverse stock splits intended to support continued Nasdaq listing, at-the-market sales agreements for common stock, and participation in investor conferences where management presents the company’s vector-borne disease strategy.
For readers tracking SXTPW, the news stream offers a view into how 60 Degrees Pharmaceuticals advances its malaria franchise, builds a babesiosis clinical program, manages its Nasdaq-listed securities, and collaborates with academic and research institutions in the U.S. and Australia. Bookmark this page to follow ongoing disclosures about trials, regulatory interactions, financing transactions, and other material events tied to the company’s warrants and underlying common stock.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has closed its previously announced registered direct offering, raising approximately $1.043 million in gross proceeds. The offering included 1,021,549 shares of common stock at $1.021 per share, priced at-the-market under Nasdaq rules.
In a concurrent private placement, the company issued unregistered short-term warrants to purchase up to 2,043,098 shares of common stock at an exercise price of $0.771 per share. These warrants are exercisable upon issuance and will expire after 24 months.
H.C. Wainwright & Co. served as the exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes. The offering was conducted under a shelf registration statement that became effective on July 18, 2024.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has announced a registered direct offering priced at-the-market under Nasdaq rules, consisting of 1,021,549 shares of common stock at $1.021 per share. The company will also issue unregistered short-term warrants in a concurrent private placement to purchase up to 2,043,098 shares at $0.771 per share, exercisable for 24 months upon issuance.
The offering, expected to close around January 30, 2025, will generate gross proceeds of $1.043 million before deducting fees and expenses. H.C. Wainwright & Co. is serving as the exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has received IRB approval for a Phase II clinical study to evaluate ARAKODA® (tafenoquine) in treating chronic babesiosis. The open-label study (NCT06656351) will assess the drug's efficacy and safety over 90 days in outpatient settings, targeting patients with presumptive chronic babesiosis who have experienced significant functional impairment for at least six months.
Patient enrollment is scheduled to begin in Q3 2025. The company estimates the total cumulative addressable market through December 2035 (U.S. patent protection end) exceeds 400,000 patients. The study aims to address an unmet medical need, as there are currently no approved treatment options for chronic babesiosis, a condition that is emerging in new regions of the U.S.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has initiated enrollment in an expanded access clinical study for tafenoquine in treating persistent babesiosis. The study aims to confirm the drug's effectiveness in patients who have failed standard care treatment and are at high relapse risk.
Recent clinical case studies showed tafenoquine achieved an 80% cure rate in five high-risk patients with persistent, relapsing babesiosis who failed prior treatments. Babesiosis, a potentially life-threatening tick-borne disease transmitted by the black-legged tick, shows increasing incidence in the Northeast U.S.
The company estimates the total cumulative accessible market through December 2035 (U.S. patent protection end) may exceed 400,000 patients. While tafenoquine is currently approved as ARAKODA for malaria prophylaxis, it has not been proven effective or received FDA approval for babesiosis treatment or prevention.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) and Tufts Medical Center have signed a Patent License Agreement to develop and commercialize tafenoquine for babesiosis treatment and prevention. The agreement establishes joint patent ownership, with 60 Degrees leading global commercialization efforts and holding exclusive rights. Tufts MC will receive royalties on net sales while retaining research rights. The collaboration aims to address an unmet medical need, as tafenoquine could potentially become the first prophylaxis available for babesiosis, a tick-borne disease affecting red blood cells. The agreement follows initial research collaboration between both organizations, resulting in U.S. Provisional Patent Application No. 63/461,060.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has expanded its tafenoquine clinical trial for babesiosis to Brigham and Women's Hospital in Boston. The double-blind, placebo-controlled study will evaluate tafenoquine combined with standard treatment for hospitalized babesiosis patients. The trial is also ongoing at Tufts Medical Center, Yale University, and Rhode Island Hospital.
The study aims to recruit 24-33 patients in summer 2025, with an interim analysis expected in early 2026. The main endpoints are time to sustained clinical resolution of symptoms and molecular cure. Recent case studies suggest tafenoquine with standard care shows high cure rates in immunosuppressed patients with relapsing babesiosis. The company estimates the total accessible market through December 2035 could exceed 400,000 patients.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported Q3 2024 financial results showing significant year-over-year growth. Sales revenue increased 164% to $135 thousand, driven by a 140% increase in ARAKODA® pharmacy deliveries. The company achieved a gross profit of $24 thousand, compared to a $20 thousand loss in Q3 2023. However, operating expenses rose to $2.16 million, and net loss was $2.27 million. A $4 million private placement was completed at $1.38 per share. Key business developments included granting University of Kentucky reference rights for ARAKODA®, securing a U.S. Army contract, and advancing clinical trials for babesiosis treatment.
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) has launched a nine-month promotional pilot for ARAKODA® (tafenoquine), an antimalarial medication. The pilot aims to increase brand awareness and utilization through virtual sales outreach and a co-pay assistance program. ARAKODA is the only FDA-approved prophylactic therapy that protects against all malaria stages, offering a convenient weekly dosing schedule.
The program includes virtual sales representatives conducting outreach to promote the co-pay program and boost sales. Data generated will inform the company on customer demographics, pricing, prescription trends, and guide future promotional efforts. This initiative precedes a planned expanded U.S. sales effort in 2025.
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) has closed a $4 million private placement of common stock and warrants. The offering included 2,898,551 shares (or equivalents) at $1.38 per share, with accompanying series A and B warrants. H.C. Wainwright & Co. acted as the exclusive placement agent. The company plans to use the proceeds for working capital, general operations, commercialization of Arakoda, and R&D. The securities were offered under Section 4(a)(2) of the Securities Act and have not been registered, limiting their sale in the United States.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has announced a $4 million private placement priced at-the-market under Nasdaq rules. The company will issue and sell 2,898,551 shares of common stock (or equivalents) at $1.38 per share, along with series A and short-term series B warrants. The warrants will have an exercise price of $1.38 per share, with series A expiring in five years and series B in 18 months from stockholder approval.
H.C. Wainwright & Co. is acting as the exclusive placement agent. The offering is expected to close around September 5, 2024. 60P plans to use the net proceeds for working capital, general operations, Arakoda commercialization, and research and development. The securities are being offered under Section 4(a)(2) of the Securities Act and have not been registered, limiting their sale in the United States.